

Aderexa 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg

Authorised

- Milbemycin oxime
- Praziquantel

Product identification

Medicine name:

Aderexa 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg

Active substance:

Milbemycin oxime

Praziquantel

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Milbemycin oxime

12.50 milligram(s) / 1.00 Tablet

Praziquantel
125.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Package description:

Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil. Cardboard box with 12 blisters, each blister contains 4 tablets (total 48 tablets).

Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil. Cardboard box with 1 blister of 4 tablets.

Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil. Cardboard box with 1 blister of 2 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

27/07/2018

Manufacturing sites for batch release:

KRKA tovarna zdravil d.d. Novo mesto
TAD Pharma GmbH

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA10774/063/002

Date of authorisation status change:

27/07/2018

Reference member state:

Ireland

Procedure number:

IE/V/0528/002

Concerned member states:

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics